Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility | Zendy

M.F. Mitwally | Zendy

Open Access

Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility

Author(s) -

M.F. Mitwally

Publication year - 2003

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/deg311

Subject(s) - letrozole , follicle stimulating hormone , infertility , pregnancy rate , ovulation , aromatase inhibitor , aromatase , medicine , endocrinology , ovulation induction , unexplained infertility , gonadotropin , estrogen , pregnancy , andrology , biology , hormone , luteinizing hormone , cancer , breast cancer , genetics

Adding clomiphene citrate (CC) to FSH for controlled ovarian stimulation (COS) decreases FSH dose required for optimum stimulation. However, because of its anti-estrogenic effects, CC may be associated with lower pregnancy rates offsetting the FSH-dose reduction benefit. Previously, we reported the success of aromatase inhibition in inducing ovulation without antiestrogenic effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research